Biosceptre

Cambridge, United Kingdom · Founded 2004 · Privately Held (backing)

Developer of chimeric antigen receptor T-cell therapy and antibody-based immune therapeutics designed to treat cancer. Biosceptre is based in Cambridge, United Kingdom and was founded in 2004. Its last reported valuation was $432 million in Feb 2024. It has raised $52.8 million.

Last reported valuation

$431.9M

Oct 2026

Priced at

—

Total raised

$52.8M

Last round

—

How much has Biosceptre raised?

$52.8Macross 0 recorded rounds

Free account

More of Biosceptre with a free account

·Watch Biosceptre: the Monday email on marks, rounds and moves

Create free account

No card required

Membership and data by Private Market View

Biosceptre investors

5 investors are on record for Biosceptre, including Innovate UK, Norcliffe Capital, Jungle Capital and McKenny-McFarlane Capital.

For fundraisers

Raising for a company like Biosceptre?

5 investors have backed Biosceptre.

See all 5 investors →

Frequently asked about Biosceptre

How much has Biosceptre raised?: Biosceptre has raised $52.8M in total across 0 recorded funding rounds.